Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Hepatitis C, Chronic 1Hepatitis C 1Fibrosis 1Diabetes Mellitus 1Cardiovascular Diseases 1Carcinoma, Hepatocellular 1

Interventions

Specimen Handling 655pembrolizumab 608Magnetic Resonance Spectroscopy 561Carboplatin 449Cisplatin 398Cyclophosphamide 396Biopsy 380Nivolumab 325Paclitaxel 323Gemcitabine 317Radiotherapy 298Bevacizumab 248Dexamethasone 223fludarabine 215Docetaxel 202durvalumab 195Oxaliplatin 189venetoclax 186atezolizumab 183Fluorouracil 177Rituximab 176Pemetrexed 173Capecitabine 170Radiation 168Doxorubicin 166Radiosurgery 161Ipilimumab 147Etoposide 142Leucovorin 140Lenalidomide 139

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
sofosbuvir-velpatasvir drug combination × 90 days × Clear all
NCT03520660 2026-06-03

People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents

National Institutes of Health Clinical Center (CC)

Phase 4 Active not recruiting
121 enrolled
Gastrointestinal

Cardiovascular Diseases, Diabetes Mellitus, Fibrosis, Hepatitis C, Carcinoma, Hepatocellular, Hepatitis C, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡